Skip to main content

Table 2 MBIC has synergistic effect in combination with selected conventional drugs

From: Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell

Drug combination Combination ratio (Dm)IC50 (μM) CI values at inhibition of DRI values at inhibition of
Drug 1 Drug 2 COMBINED 50 % 75 % 90 % 95 % 97 % 50 % 75 % 90 % 95 % 97 %
(1) (1) (1) (1) (1)
(2) (2) (2) (2) (2)
Colchicine + MBIC 1:1 3.01 ± 0.7 0.21 ± 0.02 0.076 ± 0.03 0.10 0.06 0.04 0.02 0.02 165.4 356.8 769.7 1298.3 1883.3
9.9 15.8 25.4 35.1 44.1
Nocodazole + MBIC 1:1 3.08 ± 0.5 0.21 ± 0.02 0.087 ± 0.02 0.27 0.20 0.14 0.11 0.10 20.6 31.1 46.7 61.7 75.2
4.3 5.8 7.9 9.7 11.2
Paclitaxel + MBIC 1:1 1.02 ± 0.6 0.21 ± 0.02 0.104 ± 0.06 0.35 0.28 0.23 0.20 0.18 15.3 18.4 22.1 25.0 27.3
3.4 4.2 5.1 5.9 6.5
Doxorubicin + MBIC 1:1 0.46 ± 0.7 0.21 ± 0.02 0.092 ± 0.03 0.30 0.22 0.17 0.14 0.12 12.5 17.7 25.0 31.6 37.3
4.4 5.7 7.5 9.1 10.3
  1. Table 2 displays synergistic effects of MBIC in combination with paclitaxel, colchicine, nocodazole and doxorubicin against HeLa cells by using CampuSyn software (Biosoft, Cambridge, United Kingdom; Ref. 9). Combined drugs were in 1 to 1 ratio. After entering dose and effects of combined drugs individually and in combination, software generates Combination Index (CI) value at 50 to 97 % inhibitions of HeLa cells treated with combined drug (1) (conventional drugs) and drug (2) (MBIC). Additionally, table contains dose reduction index (DRI) for drug (1) and drug (2) which suggest how many fold of each drug in combination can be reduced while having same effect. Data were mean ± SD of two independent experiments. (P < 0.05)